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Objective: This study was undertaken to compare 1-year and 5-year results of endovascular repair of abdominal aortic
aneurysm (AAA) with the Guidant/EVT bifurcated graft system with results of open repair.
Methods: This was a prospective, nonrandomized, concurrent controlled study that compared results of endovascular
versus open repair of AAA. The Phase II study with the EGS delivery system included 268 patients in 18 US medical
centers; and the Phase III trial with the Ancure delivery system incuded 305 patients in 21 US institutions. Data were
internally and externally audited and subjected to periodic review by the US Food and Drug Administration. The control
group of 111 patients were excluded from endovascular repair with a tube graft because of anatomic considerations, but
were otherwise comparable to the experimental group. Patients in the control group underwent conventional open
surgical repair concurrently with patients who underwent EGS repair in 18 US institutions.
Results: Five hundred thirty-one of 573 patients (92.7%) underwent successful implantation of the Guidant/EVT
bifurcated endograft. The combined major morbidity and mortality in the endograft group was 28.8%, compared with
44.1% in the open control group. Additional benefits in the endograft group included shorter hospital stay (2 days vs 6
days), less surgical blood loss (400 mL vs 800 mL), and less intensive care unit use (33% vs 94%). These early results are
reported on an intent-to-treat basis; in all patients an attempt was made to treat with the endovascular graft, including
those patients in whom conversion to standard open repair was necessary during the primary procedure. Three hundred
nineteen patients were selected for long-term follow-up to 5 years, on the basis of date of implantation; ie, patients with
the earliest implantations were followed up for 5 years. The primary purpose of long-term follow-up was to obtain data
on long-term efficacy of the graft; thus only patients in whom implantation was successful were selected. No patient has
experienced an aneurysm rupture to date. Survival (Kaplan- Meier method) in the experimental group was 68.1%,
compared with 77.2% in the control group (P  NS). At 60 months, 74.4% of patients (32 of 43) were free of endoleak.
There were no type I or type III endoleaks remaining. Aneurysm sac diameter decreased or remained stable in 97.6% of
patients (41 of 42) and increased in only 1 patient. During the course of long-term follow-up, post-procedural conversion
to open repair was required in only 9 patients (2.8%).
Conclusion: The EVT/Guidant bifurcated graft is effective in preventing AAA rupture, and long-term survival is
comparable to that with open repair. (J Vasc Surg 2003;38:46-55.)
The first endovascular repair of abdominal aortic aneu-
rysm (AAA) was reported by Parodi et al1 in 1991. The first
device specifically for endovascular repair of AAA was man-
ufactured by Endovascular Technologies (EVT) and sub-
sequently acquired by Guidant (Menlo Park, Calif). The
first implant of an EVT experimental device, an aorto-aortic
tube graft, was performed at UCLA Medical Center on
February 10, 1993, under an Investigational Device Ex-
emption (IDE) clinical trial.2,3 It rapidly became evident
that only a small percentage of AAA could be treated with a
tube graft. In 1994 EVT released their first bifurcated
graft,4 a partially supported, unibody system, and began
clinical evaluation with the initial implants in September
1994. Shortly thereafter, production of both prostheses
was stopped because of attachment system fracture in some
patients.5 The attachment systems were reengineered, and
the Endovascular Graft System was released in 1995. Sub-
sequently a more streamlined delivery system was devel-
oped, which deployed the same endograft but was called
the Ancure system.
Guidant received approval from the US Food and Drug
Administration (FDA) for commercialization in September
1999. One condition of approval was that a cohort of the
overall investigational group be followed up for 5 years.
The objective of this report is to present, for the first
time, the entire Phase II and Phase III bifurcation graft
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experience. This includes previously reported EGS data6,7
and the new Ancure data. In addition, we report data up to
5 years for the cohort of patients selected for long-term
follow-up. The results from the investigational group are
compared with those in a control group of 111 patients
undergoing standard open repair and followed up over the
same period.
METHODS
Data from two prospective multicenter, nonrandom-
ized, but clinically controlled studies are reported. The
EGS component was conducted at 18 sites in the United
States, and the Ancure component at 21 US institutions
(Appendix, online only). Patient selection, technique of
implantation, and follow-up protocol have been described
previously.4,6-9
From November 22, 1995, to February 12, 1998, 268
patients were enrolled for implantation of the EGS system.
After introduction of the Ancure delivery system, an addi-
tional 305 patients were entered into the study. An addi-
tional 19 patients underwent endograft implantation, off
protocol, on a compassionate-use basis. These patients did
not meet inclusion criteria for the study, and their data are
excluded from the analysis.
The control group was composed of 111 patients who
were excluded from endovascular repair with a tube graft
on the basis of anatomic considerations but who were
otherwise comparable to the experimental group and un-
derwent conventional surgical repair. Most of these pa-
tients would have been candidates for endovascular repair
with a bifurcated graft if one had been available at enroll-
ment. Ninety-four of these patients underwent open repair
with a tube graft, and 17 patients received a bifurcated
graft.
All study patients were followed up according to pro-
tocol for a minimum of 1 year. Early safety data are analyzed
on an intent-to-treat basis and include all patients in whom
an attempt to treat was made. Three hundred nineteen
patients (242 EGS, 77 Ancure) were selected for long-term
(5 years) follow-up on the basis of date of implantation.
The long-term group included all patients who left the
operating room after successful implantation; it excluded
those who underwent intraoperative conversion. All 111
control patients are being followed up concurrently for 5
years.
The study protocol included follow-up visits at 1, 6,
and 12 months after implantation and annually thereafter.
The follow-up protocol included physical examination,
plain abdominal radiography, duplex scanning of the ab-
dominal aorta, and contrast medium–enhanced computed
tomography (CT) of the abdomen and pelvis. These studies
were reviewed by the investigators and the respective diag-
nostic services of the individual institutions. All studies
from the EGS cohort and those patients in the Ancure
cohort selected for long-term follow-up were then sent to
an independent core laboratory for impartial review. Core
laboratory interpretation and analysis formed the database
for this report. The most recent core laboratory report is
from August 2002 and includes all data reported by the
core laboratory at that time.
Outcome criteria and definitions adhere, where possi-
ble, to the updated reporting standards for endovascular
AAA repair as reported by Chaikof et al10 in May 2002.
However, because these studies were designed and initiated
long before the current standards were established, it was
not possible to retrospectively apply all of these standards.
The end point of death was compared between the
investigational (endograft) and control (open repair)
groups with life-table methods and is expressed as freedom
from death. For life table analysis, the log-rank test was
used to determine the significance of difference between
groups. P  .05 was considered significant. All patients
entered into the investigational or control groups were
followed up within that group in an intent-to-treat format
for safety data to 30 days; solely on the basis of date of
implantation, a group of patients who underwent successful
implantation were followed up for 5 years. Comparisons
between EGS and Ancure groups and between combined
bifurcated versus control groups were made with the Fisher
exact test, unless otherwise stated.
RESULTS
Periprocedural outcome. Demographic and comor-
bidity data are summarized in Table I. Data for patients in
the earlier EGS group (N  268) were compared with
those for patients in the Ancure group (N 305) with the
Fisher exact test. Although the demographics and comor-
bid conditions were similar in both groups, they did differ
significantly in five comorbid conditions. The EGS group
had a significantly higher incidence of coronary artery dis-
ease (61.6% vs 52.5%; P  .035), stroke (12.7% vs 5.2%; P
 .002), and peripheral arterial occlusive disease; 13.8% vs
7.2%; P  .013). In the Ancure group significantly more
patients had arrhythmia (50.8% vs 33.2%; P  .001) com-
pared with the EGS group. Finally, incidence of myocardial
infarction was higher in the EGS group, though not statis-
tically significant (39.2% vs 31.1%; P  .053). Data for the
combined investigational group (N  573) were then
compared with data for the control group (N  111). The
parameters were comparable, with three statistically signif-
icant differences: in the investigational group there was a
significantly greater predominance of male gender (91.5%
vs 76.6% P  .001), significantly more patients with ar-
rhythmia (42.6% vs 18.9%;, P  .001), and significantly
fewer smokers (82.0% vs 90.1%; P  .037). Both groups
were at relatively high risk, with 88% of patients in the
combined investigational group and nearly 87% of patients
in the control group with anesthesia risk III or IV. Given
that the investigational and control groups were not ran-
domized, the two groups were reasonably similar and are
therefore considered comparable.
Table II shows the distribution of aneurysm diameter
treated in the EGS, Ancure, and combined groups as
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compared with the control group. There are no statistically
significant differences in aneurysm size distribution be-
tween EGS and Ancure, and no statistically significant
differences between the total investigational group and the
control group (2 test). Some patients enrolled in the
studies had small aneurysms, with indications for repair
including symptoms, eg, distal emboli or pain, or specific
findings, eg, concomitant iliac aneurysm, saccular aneu-
rysm, or rapid enlargement.
Thirty-day outcome. Resource use, on the basis of
intent-to-treat, is summarized in Table III. Median hospi-
tal stay for the EGS group was 3 days and for the Ancure
group was 2 days, compared with 6 days for the open-repair
Table II. Aneurysm diameter distribution
Diameter range (mm)
EGS bifurcated
group (N  268)
Ancure bifurcated
group (N  305) Total (N  573)
Control
(N  111)
n % n % n % n %
30 0 0.0 1 0.3 1 0.2 0 0.0
30-39 7 2.6 5 1.6 12 2.1 2 2.0
40-49 75 28.2 87 28.5 162 28.4 28 27.5
50-59 116 43.6 149 48.9 265 46.4 42 41.2
60-69 44 16.5 48 15.7 92 16.1 21 20.6
70-79 19 7.1 8 2.6 27 4.7 6 5.9
80-89 5 1.9 5 1.6 10 1.8 3 2.9
90 0 0.0 2 0.7 2 0.4 0 0.0
Unknown
P*
2 0
.190
2 9
.832
*Comparison of EGS vs Ancure and comparison of all bifurcated grafts with controls, 2 test. Cells with number less than 3 combined with adjacent cell.
Table I. Demographic data and comorbid conditions
Variable
EGS bifurcated
graft
(N  268)
Ancure
bifurcated
graft
(N  305)
P*
Total
(N  573)
Control
(N  111)
P†n % n % n % n %
Male gender 240 89.6 284 93.1 .137 524 91.5 85 76.6 .001
Age (y)
(mean  SD)
72.7  7.7 72.8  7.8 .878‡ 72.8  7.8 71.6  7.0 .146‡
White race 254 94.8 295 96.7 .298 549 95.8 108 97.3 .600
CAD 165 61.6 160 52.5 .035 325 56.7 68 61.3 .403
MI 105 39.2 95 31.1 .053 200 34.9 43 38.7 .450
Arrhythmia 89 33.2 155 50.8 .001 244 42.6 21 18.9 .001
Valvular heart disease 32 11.9 40 13.1 .706 72 12.6 10 9.0 .340
CHF 35 13.1 239 9.5 .186 64 11.2 8 7.2 .241
Stroke 34 12.7 16 5.2 .002 50 8.7 13 11.7 .368
Hypertension 166 61.9 196 64.3 .603 362 63.2 79 71.2 .129
PAOD 37 13.8 22 7.2 .013 59 10.3 12 10.8 .865
COPD 77 28.7 71 23.3 .152 148 25.8 33 29.7 .411
Smoking 217 81.0 253 83.0 .586 470 82.0 100 90.1 .037
Diabetes 32 11.9 32 10.5 .597 64 11.2 11 9.9 .868
Renal insufficiency 18 6.7 9 3.0 .047 27 4.7 5 4.5 1.000
Anesthesia risk
I 1 0.4 1 0.3 .214 2 0.4 1 0.9 .399
II 36 13.5 26 8.5 62 10.9 14 12.6
III 175 65.8 217 71.1 392 68.7 79 71.2
IV 54 20.3 61 20.0 115 20.1 17 15.3
Unknown 2 0 2 0
CAD, Coronary artery diseases; MI, myocardial infarction; CHF, congestive heart failure; PAOD, peripheral artery obstructive disease; COPD, chronic
obstructive pulmonary disease.
*Comparison of EGS vs Ancure grafts, using Fisher exact test.
†Comparison of all bifurcated grafts vs control, Fisher exact test.
‡Comparison of mean age, t test.
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control group. Thirty-eight percent of the EGS group and
29% of the Ancure group spent time in an intensive care
unit (ICU), compared with 94% of the control group.
Median operative time was 130 minutes in the EGS group,
184 minutes in the Ancure group, and 167 minutes in the
control group. Median blood loss was 300 mL in the EGS
group, 450 mL in the Ancure group, and 800 mL in the
control group.
Thirty-day morbidity and mortality data are summa-
rized in Table IV. While there was a trend toward reduced
mortality in the investigational group compared with the
control group (1.7% vs 2.7%), the difference was not statis-
tically significant. The rate of specific adverse events per
group are listed in Table IV. Major complications are
combined in what is called the IDE composite risk; under
the IDE composite risk index, each patient with at least one
moderate or severe adverse event is counted. This compos-
ite complications expression was done with FDA approval
to compare overall risk between the investigational and
control groups. The IDE composite includes major respi-
ratory, cardiac, hemorrhagic, bowel, wound, renal, arterial
trauma, neurologic, and ischemic complications, and
death. There is no difference in the IDE composite com-
plications between the EGS and Ancure groups, but there is
a major difference between the investigational and control
groups. The combined complication rate in the investiga-
Table IV. Thirty-day morbidity and mortality
EGS
bifurcated
group
(N  268)
Ancure
bifurcated
group
(N  305)
P*
Total
(N  573)
Control
(N  111)
P†n % n % n % n %
Mortality 2.6 7 1.0 3 .201 1.7 10 2.7 3 .453
Major complications
(IDE composite)‡
28.7 77 28.9 88 1.000 28.8 165 44.1 49 .002
Arterial trauma 16.0 43 10.2 31 .045 12.9 74 0.0 0 .001
Bleeding 15.7 42 20.7 63 .131 18.3 105 39.6 44 .001
Bowel 3.0 8 0.3 1 .015 1.6 9 8.1 9 .001
Cardiac 13.4 36 6.6 20 .007 9.8 56 20.7 23 .002
Coagulopathy 3.0 8 1.0 3 .125 1.9 11 4.5 5 .158
Deep vein thrombosis 1.1 3 0.7 2 .669 0.9 5 0.9 1 1.000
Embolism or lower
extremity ischemia
3.0 8 5.2 16 .212 4.2 24 0.9 1 .102
Hematoma 9.3 25 4.9 15 .048 7.0 40 1.8 2 .048
Impotence 0.0 0 0.0 0 NA 0.0 0 1.8 2 .026
Paraplegia or paraparesis 0.4 1 0.0 0 .468 0.2 1 0.0 0 1.000
Prosthetic thrombosis 2.6 7 3.3 10 .806 3.0 17 0.0 0 .090
Renal insufficiency 8.2 22 3.0 9 .009 5.4 31 1.8 2 .114
Respiratory 10.1 27 1.0 3 .001 5.2 30 22.5 25 .001
Stroke 0.7 2 1.0 3 1.000 0.9 5 0.9 1 1.000
Transient ischemic attack 0.7 2 0.3 1 .602 0.5 3 0.0 0 1.000
Wound 3.4 9 6.6 20 .088 5.1 29 1.8 2 .208
IDE, Investigational Device Exemption clinical trial; NA, data not available.
*Comparison of EGS vs Ancure Fisher exact test.
†Comparison of all bifurcated grafts vs controls, Fisher exact test.
‡IDE composite is expression of combined major complications, as listed in table.
Table III. Resource use
Outcome measure EGS Ancure P Total Control P
Median hospital stay (d) 3 (262) 2 (302) .0028* 2 (564) 6 (108) .0001*
ICU stay (h)
Median 24 (101) 24.5 (87) .2067* 24 (188) 27 (104) .0154*
Number 102/261 87/302 189/563 107/111
Patients with ICU stay (%) 39 29 .0121† 34 96 .0001†
Median operative time (min) 197 (266) 184 (305) .0794* 190 (571) 167 (111) .0001*
Median operative blood loss (mL) 300 (263) 450 (300) .0001* 400 (563) 800 (111) .0001*
Numbers in parentheses represent number of patients.
*Wilcoxon rank-sum test.
†Fisher exact test.
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tional group was 28.8%, compared with 44.1% in the
control group (P  .002). Among specific adverse event
categories, more arterial trauma and hematomas were ob-
served in the investigational group (P .001 and P .048,
respectively), whereas the control group experienced sig-
nificantly more bleeding, bowel, cardiac, and respiratory
complications (P .002), and a greater incidence of impo-
tence (P  .026).
One-year outcome. Adverse events related to the en-
dograft are summarized in Table V, with freedom-from
analysis (Kaplan-Meier method) for aneurysm rupture,
postoperative conversion, graft thrombosis, and graft mi-
gration. It is important that there have been no aneurysm
ruptures among either the EGS or the Ancure groups in
this clinical trial. Freedom from graft thrombosis at 1 year is
94.6%. Data for 2 patients in the combined endograft
group have been interpreted by the core laboratory as
showing graft migration, and freedom from migration at 1
year is 99.8%. One of these patients subsequently under-
went open repair, and one continues to function without
consequence. The overall intraoperative conversion rate to
open repair was 7.2% (41 of 573 patients) and the freedom
from postoperative conversion for the combined group at 1
year was 99.4%. There was no significant difference be-
tween the EGS and Ancure groups with respect to rate of
postoperative conversion, but the EGS group did experi-
ence a significantly higher rate of intraoperative conversion
(9.7% vs 4.9%; P  .034).
Table VI analyzes reasons for conversion to open repair
and divides them into early or intraoperative conversion
(30 days) and late conversion (30 days). Five hundred
thirty-one patients (92.7%) underwent successful implanta-
tion. The total early conversion rate was 7.3%. Inability to
access the aneurysm accounted for 2.1%. These should be
considered elective conversions because a decision was
made to proceed with aneurysm repair at the original
Table VI. Reasons for conversion to open repair
EGS (N  268)
Ancure
(N  305) Total (N  573)
P*n % n % n %
Total intraoperative
conversion 30 days
26 9.7 16 5.2 42 7.3 .053
Failure to access 11 4.1 1 0.3 12 2.1 .002
Failure to place accurately 15 5.6 15 4.9 30 5.2 .851
Arterial trauma 4 0 4 —
Failure to retract jacket 0 7 7 —
Improper graft position 1 2 3 —
Endoleak 2 0 2 —
Compromised limb flow 0 2 2 —
Twist 3 3 6 —
Unable to remove catheter 5 0 5 —
Change in anatomy 0 1 1 —
Total late conversion 30
days and 12 mo
2 0.7 0 0.0 2 0.3 .218
Endoleak and aneurysm
enlargement
2 0.7 0 0.0 2 0.3 .218
*Comparison of EGS vs Ancure, Fisher exact test.
Table V. Adverse endograft-related events at 12 months
Freedom from event at 12 months EGS (N  268) Ancure (N  305) Combined (N  573) P*
Aneurysm rupture (%) 100.0 100.0 100.0 NS
Postoperative conversion (%) 99.1 99.7 99.4 .798
Graft thrombosis (%) 94.6 94.5 94.6 .626
Graft migration (%) 99.6 100.0 99.8 .293
Postoperative interventions to treat
compromised limb flow (%)
90.7 89.4 90.2 .652
Intraoperative event rates
Conversion 26/268 (9.7%) 15/305 (4.9%) 41/573 (7.2%) .034†
Interventions to treat
compromised limb flow
68/242 (28.1%) 92/290 (31.7%) 160/532 (30.1%) .393†
*Comparison of EGS vs Ancure, log-rank test.
† Comparison of EGS vs Ancure, Fisher exact test.
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operation rather than postponing repair to a later date. Of
the early conversions, 5.2% (30 of 573) were due to a
variety of reasons why the graft could not be accurately
placed; these should be considered mandatory conversions.
The late conversion rate was extremely low. Two patients
(0.7%) in the EGS group underwent late conversion be-
cause of endoleak and aneurysm enlargement. There were
no late conversions within a 12-month interval in the
Ancure group. The late conversion rate for the combined
EGS and Ancure group within the first year was 0.3%.
Table VII reports the types of interventions used to
improve graft limb blood flow. Two hundred sixteen pa-
tients required intervention because of compromised limb
flow, ranging from stenosis to complete occlusion. The
types and timing of interventions are summarized in Table
VII. This represents 40.6% of the patients, or approxi-
mately 20.3% of limbs at risk. A few patients underwent
bilateral limb interventions. In about 30% of patients inter-
ventions to support limb patency were performed during
the primary procedure; about 10% of patients required a
post-procedural intervention to treat symptoms.11
Freedom from postoperative intervention to treat re-
duced limb flow up to 365 days is expressed with the
Kaplan-Meyer method (Fig 1).
Five-year outcome. Patients selected for long-term
follow-up included 319 who received the endovascular
bifurcated graft (experimental group) and 111 who under-
went standard open repair (control group). In accordance
with an agreement between Guidant and the FDA, patients
were selected for long-term follow-up solely on the basis of
date of graft implantation; those who received the implant
from initiation of the study to a specified cut-off date were
selected for 5-year follow-up. Thus the 5-year data repre-
sent the earliest experience with the devices. The primary
purpose of prolonged follow-up was to obtain data on
long-term efficacy of the graft; thus only patients in whom
the graft was successfully implanted were selected. Among
the 268 patients enrolled in the EGS study, implantation
was successful in 242 patients, and all of these are included
in the long-term follow-up cohort. In the 305 patients who
received the Ancure graft, implantation was successful in
290 patients; the first 77 patients underwent the procedure
before the long-term follow-up cut-off date and are thus
included in the cohort. Survival curves (Kaplan-Meier
method) for the long-term follow-up experimental group
and the control group are shown in Fig 2. The experimental
group data include follow-up data for the 9 patients in
whom late conversion to open repair was necessary. The
log-rank test was used to compare both curves. There was
no statistically significant difference in survival at any point
along the curve up to and including 60 months (P 
.1033). The life table for derivation of survival is repre-
sented in Table VIII (online only). The probable causes of
death in the experimental and control groups are summa-
rized in Table IX.
During the 60-month follow-up, 9 of 319 patients
(2.82%) underwent conversion to open repair. The reasons
for late conversion, and the interval during the course of
follow-up, are summarized in Table X.
Information concerning perigraft flow and its influence
on aneurysm diameter over time was reported to us by the
core laboratory to maintain objectivity in analysis of plain
radiographs, duplex abdominal scans, and contrast-en-
hanced CT scans of the abdomen and pelvis. Data concern-
ing perigraft flow as a function of follow-up interval are
summarized in Table XI, including number and percentage
of patients with and without perigraft flow of all types, with
a secondary breakdown that itemizes attachment site flow,
Table VII. Types of interventions to optimize bifurcated graft limb flow
Intraoperative Postoperative Total
% 95% CI* % 95% CI* % 95% CI*
Bifurcated EGS
Stent† 14.0 34/242 9.9, 19.1 7.4 18/242 4.5, 11.5 21.5 52/242 16.5, 27.2
PTA only 11.6 28/242 7.8, 16.3 NA 11.6 28/242 7.8, 16.3
Surgical‡ 2.1 5/242 0.7, 4.8 1.2 3/242 0.3, 3.6 3.3 8/242 1.4, 6.4
Other§ 0.4 1/242 0.0, 2.3 0.4 1/242 0.0, 2.3 0.3 2/242 0.1, 3.0
Total 68/242 22/242 90/242
28.1% 9.1% 37.2%
Bifurcated Ancure
Stent† 23.4 68/290 18.7, 28.8 5.9 17/290 3.4, 19.2 29.3 85/290 24.1, 34.9
PTA only 5.2 15/290 2.9, 8.4 NA 5.2 15/290 2.9, 8.4
Surgical‡ 2.8 8/290 1.2, 5.4 2.8 8/290 1.2, 5.4 5.5 16/290 3.2, 8.8
Other§ 0.3 1/290 0.0, 1.9 1.7 6/290 0.6, 4.0 2.1 6/290 0.8, 4.5
Total n/N 92/290 30/290 122/290
31.7% 10.3% 42.1%
PTA, Percutaneous transluminal angioplasty; NA, data not available.
*Clopper-Pearson exact 95% confidence intervals.
†Includes some subjects who underwent PTA or other nonsurgical interventions and stent placement.
‡Includes femor-femoral bypass and surgical revision. Includes some patients who may have undergone stent, placement, PTA, or other nonsurgical
interventions.
§Includes thrombolysis, thrombectomy, and anticoagulant therapy.
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branch flow, flow from unknown source, and indetermi-
nate flow. As the study progressed, delay in analyzing the
data and reporting by the core laboratory increased. For
this reason, the number of patients with complete data at 5
years is still relatively small. It is noteworthy, however, that
there has been a progressive decline in percentage of pa-
tients with perigraft flow over time, up to and including 5
years. Thus 42.2% of patients at discharge had perigraft
flow, and this percentage decreased to 16.3% by 60
months. Furthermore, by 60 months no patients had type
Fig 1. Kaplan-Meier curve indicates percentage of patients free of postoperative interventions up to 1 year of
follow-up. There are no differences between the EGS and Ancure series. Most interventions occurred within the first 90
days after implantation; after that, no interventions were necessary. Thus at 1 year 92% of patients were free of any
postoperative intervention to treat reduced limb flow.
Fig 2. Kaplan-Meier graphic representation of freedom from mortality over 60 months. Data for the long-term
experimental cohort, including patients who underwent postoperative conversion to open repair, and the control group
were compared with log-rank testing, with 95% confidence intervals noted (vertical bars). There are no statistically
significant differences between the two groups.
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I, or attachment site, flow. Table XII (online only) summa-
rizes mean aneurysm diameter in the experimental group as
a function of time after implantation. Thus mean diameter
at hospital discharge was 52.4 mm, which decreased to
38.9 mm by 60 months.
Table XIII (online only) examines in more detail the
effect of time on aneurysm diameter and identifies patients
in whom aneurysm diameter decreased by 5.0 mm or more,
remained stable or aneurysm sac size was unchanged with
diameter change of  4.9 mm, or aneurysm sac increased
by 5.0 mm or more. By 60 months, aneurysm sac size
decreased in 78.6% of patients, remained stable in 19.0%,
and increased in only 2.4%. These data are summarized in a
histogram in Fig 3.
The influence of presence or absence of perigraft flow
of any type on aneurysm sac diameter change at the end of
36, 48, and 60 months is summarized in Table XIV (online
only). Analysis of these data reveals that the absence of
perigraft flow was significantly associated with a decrease in
sac size at 36 months (P .0001), 48 months (P .0556,
marginally significant), and 60 months (P .0001). Over-
all, few patients experienced increase in sac size at any time
during follow-up. At 36 months, sac size had increased in 3
patients, 2 with perigraft flow and 1 without perigraft flow.
Among patients with flow and aneurysm size evaluated at
48 and 60 months, none demonstrated an increase in sac
size. Data regarding endoleak are unavailable for the 1
patient with aneurysm growth at 48 and 60 months.
DISCUSSION
The objective of AAA repair is to prevent future aneu-
rysm rupture. To this end the EVT/Guidant Bifurcation
Trial has been uniquely successful. No aneurysm rupture
has been reported in patients followed up for 5 years.
Bernhard et al12 reported a collective series of seven rup-
tured aneurysms in patients with Guidant endografts in
place. All seven ruptures occurred in patients with tube
grafts; no ruptures were reported in patients with bifur-
cated grafts during the trial or after commercialization.
Nonetheless, their report should serve to emphasize the
importance of mandatory scheduled surveillance with con-
trast-enhanced CT to detect both early and late-onset
endoleak and to identify possible aneurysm sac enlarge-
ment. Failure to do this will result in some aneurysms
progressing to enlargement and rupture. Since aneurysm
sac enlargement did not correlate with presence or absence
of endoleak, it would be tempting to perform CT without
contrast medium and simply measure sac size. Certainly this
practice would be acceptable in patients with contrast me-
dium allergy or compromised renal function. However, if
the practice were routinely applied, spontaneous closure of
endoleak or late-onset endoleak would be missed as specific
events. Both events influence frequency of CT surveillance.
The results reported in this trial are also influenced by
strict adherence to protocol inclusion and exclusion crite-
ria. Deviation from these criteria in patient selection, and
improper supervision and training of operators involved in
device implantation will likely result in poor early and late
outcome.
The benefits of endovascular repair over conventional
open repair are perhaps best seen in the reduction in 30-day
morbidity. In this series, major morbidity and mortality
were defined by the IDE composite safety parameter, which
represents the aggregate of death and major complications
occurring within 30 days of operation. Clearly the endovas-
cular approach was beneficial; only 28.8% of patients in the
experimental group demonstrated major morbidity or mor-
tality, within this definition, compared with 44.1% of pa-
tients in the open repair control group with adverse out-
come. Specific adverse events differed among groups
(Table IV). Patients in the investigational endovascular
group were more likely to have arterial trauma and hema-
toma; this is explained by the mechanics of graft implanta-
tion. Patients in the surgical control group were more likely
to have bleeding, bowel, cardiac, and respiratory problems.
When the parameter of 30-day mortality is examined alone,
there is a trend toward less mortality in the endovascular
Table IX. Probable cause of death, bifurcated and
control groups
Cause of death
Bifurcated
(N  319)
Control
(N  111)
n % n %
Aneurysm rupture 0 0.0 0 0.0
Cardiovascular-related 32 10.0 6 5.4
Pulmonary-related 12 3.8 4 3.6
Other 29 9.1 10 9.0
Total 73 22.9 20 18.0
% freedom from mortality
(survival) per Kaplan-Meier
analysis at 60 mo
68.1 77.2
95% confidence interval around
freedom from mortality, per
Kaplan-Meier analysis at 60 mo
0.608, 0.754 0.678, 0.867
Table X. Timing of postoperative conversion to open
repair
Time of conversion
Bifurcated graft
(N  319) Reason for conversion
After day of procedure
and 30 d
1 Reduced limb
patency
30 d and 12 mo 1 Perigraft flow
1 Perigraft flow
12 and 24 mo 0 —
24 and 36 mo 1 Endograft infection
1 Reduced limb
patency
36 and 48 mo 1 Perigraft flow
1 Aneurysm
enlargement*
48 and 60 mo 1 Endograft infection
1 Migration
Total conversions 9 (2.82%)
*Without evidence of perigraft flow.
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group compared with the control group (1.7% vs 2.7%).
However, this difference is not statistically significant.
The immediate benefits of endovascular repair com-
pared with open repair include less 30-day morbidity; re-
duced resource use, including short hospital stay (2 days vs
6 days), decreased blood loss (400 mL vs 800 mL);, and
reduced ICU use (33% vs 94%). These benefits must be
balanced against the unique risks of endovascular repair,
including endoleak and possible need for early or late
conversion to open repair. Despite these added risks, long-
term survival in the experimental group was comparable
with that in the control group. This outcome may have
been achieved by the rigorous surveillance mandated by the
experimental protocol and willingness to convert to open
repair when necessary. Only 9 patients (2.82%) required
late conversion to open repair. However, these patients
were equally distributed over the 60 months of follow-up,
emphasizing the necessity of continual follow-up for the life
of the patient.
Finally, with the excellent early benefits and 5-year
outcome comparable to that with open repair, can we say
that endovascular repair has become the procedure of
choice in patients who meet the anatomic selection criteria?
Certainly, in the average elderly patient with multiple co-
morbid conditions endovascular repair should be consid-
ered the procedure of choice, provided the patient is suit-
ably informed about the unique risks of endografts, the
need for continual surveillance, and the small but finite
need for late conversion to open repair. However, the
relatively young and otherwise healthy person with AAA, in
whom life expectancy exceeds our currently available fol-
low-up data, is best advised to undergo conventional repair
until longer follow-up information is available.
We thank Lois Kellerman for her contribution as bio-
statistician.
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